A PiggyBac-based PSR vector system for construction of stable self-inactivating γ-retrovirus producer cell lines

Introduction γ-retroviral vectors (RVs) are broadly applied in cell therapy, yet self-inactivating γ-retroviral vectors (SIN-RVs), which possess superior biosafety, are conventionally produced via transient transfection and face major barriers for large-scale manufacturing. Here, we established a PiggyBac transposon-based platform, termed PSR, to generate stable SIN-RV producer cells. Methods The PSR platform was constructed using the pSRS11.SF.GFP backbone. CopGFP reporter and puromycin resistance markers were integrated to simplify screening of stable producer cell populations. These markers are exclusively expressed in the vector producer cell lines rather than in transduced target cells, and are not packaged into SIN-RV particles, representing a favorable safety feature. The SFFV promoter was used as the internal promoter, and the U3 region within the 5′-LTR was replaced with an RSV chimeric promoter. PSR.EGFP was packaged to characterize vector production, and SIN-RV encoding SynCAR190 was further generated as an application example. Results and conclusion Viral supernatant of PSR.EGFP derived from Phoenix-Ampho cells reached a titer of 1.6 × 10 7 TU/mL, which is >100-fold higher than the 1.3 × 10 5 TU/mL from PG13 cells, supporting Phoenix-Ampho as a highly suitable packaging cell line under our experimental conditions. With polybrene treatment, one round of transduction using PSR.EGFP supernatant achieved 70.2% transduction efficiency in Jurkat-T cells (MOI = 10). Among 15 monoclonal PSR.SynCAR190 clones, clone A190–5 was selected for characterization. This clone produced viral supernatant with a titer of 2.39 × 10 6 TU/mL and yielded a 56.27% transduction efficiency in primary T cells (MOI = 6), with the observed titer reduction consistent with the large transgene insert size. In vitro assays indicated that SynCAR190-T cells preferentially targeted CD19 + BCMA + double-positive tumor cells while exhibiting minimal cytotoxicity against single-positive cells. These preliminary functional validations are consistent with the intended gating design. Collectively, this engineered PSR platform provides a feasible approach for generating stable SIN-RV producer cells at laboratory scale.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-12
DOI
https://doi.org/10.3389/fimmu.2026.2010369
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A PiggyBac-based PSR vector system for construction of stable self-inactivating γ-retrovirus producer cell lines

Jianxun Wang, Wenjuan Wang, Hanyi Chen, Wei Hu et al.
Frontiers in Immunology
Virus-based gene therapy research
article

A PiggyBac-based PSR vector system for construction of stable self-inactivating γ-retrovirus producer cell lines

Jianxun Wang, Wenjuan Wang, Hanyi Chen, Wei Hu, Sui Xiang, Ye Zhang, Jing Chen, Jiajia Fang
article en

Abstract

Introduction γ-retroviral vectors (RVs) are broadly applied in cell therapy, yet self-inactivating γ-retroviral vectors (SIN-RVs), which possess superior biosafety, are conventionally produced via transient transfection and face major barriers for large-scale manufacturing. Here, we established a PiggyBac transposon-based platform, termed PSR, to generate stable SIN-RV producer cells. Methods The PSR platform was constructed using the pSRS11.SF.GFP backbone. CopGFP reporter and puromycin resistance markers were integrated to simplify screening of stable producer cell populations. These markers are exclusively expressed in the vector producer cell lines rather than in transduced target cells, and are not packaged into SIN-RV particles, representing a favorable safety feature. The SFFV promoter was used as the internal promoter, and the U3 region within the 5′-LTR was replaced with an RSV chimeric promoter. PSR.EGFP was packaged to characterize vector production, and SIN-RV encoding SynCAR190 was further generated as an application example. Results and conclusion Viral supernatant of PSR.EGFP derived from Phoenix-Ampho cells reached a titer of 1.6 × 10 7 TU/mL, which is >100-fold higher than the 1.3 × 10 5 TU/mL from PG13 cells, supporting Phoenix-Ampho as a highly suitable packaging cell line under our experimental conditions. With polybrene treatment, one round of transduction using PSR.EGFP supernatant achieved 70.2% transduction efficiency in Jurkat-T cells (MOI = 10). Among 15 monoclonal PSR.SynCAR190 clones, clone A190–5 was selected for characterization. This clone produced viral supernatant with a titer of 2.39 × 10 6 TU/mL and yielded a 56.27% transduction efficiency in primary T cells (MOI = 6), with the observed titer reduction consistent with the large transgene insert size. In vitro assays indicated that SynCAR190-T cells preferentially targeted CD19 + BCMA + double-positive tumor cells while exhibiting minimal cytotoxicity against single-positive cells. These preliminary functional validations are consistent with the intended gating design. Collectively, this engineered PSR platform provides a feasible approach for generating stable SIN-RV producer cells at laboratory scale.

Frontiers in ImmunologyVol. 17
China Three Gorges University (CN), Beijing University of Chinese Medicine (CN)
Good health and well-being
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon